Hopkins Biologist Saul Sharkis Dies at 72; Studied Blood Stem Cells’ Role in BMT

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Saul Sharkis, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died Sept. 4. He was 72.

Sharkis was a professor of oncology at the Johns Hopkins University School of Medicine and a faculty member in the Johns Hopkins Kimmel Cancer Center for more than 40 years.

A native of New York, Sharkis earned his B.A. from Hunter College and his master’s and doctoral degrees from New York University. After completing his postdoctoral research at National Naval Medical Center in Bethesda, Maryland, he was recruited to the faculty of the Johns Hopkins University School of Medicine’s Department of Oncology.

Sharkis was among the first to isolate and study hematopoietic stem cells. His research was important to the progress of bone marrow and stem cell transplants because it helped reveal the mechanisms of engraftment. His work also uncovered the biology of stem cells, isolating and tracking a stem cell population to show that small numbers of stem cells can reconstitute bone marrow following transplant.

He also studied the plasticity of blood stem cells and developed research models to explore their capacity to develop into other cells, particularly epithelial cells in the liver, pancreas, kidney, breast and intestine. These cells line the organs and are often the site where cancers begin. His hope was that one day, stem cells could be use as cellular therapy to treat cancers.

“Saul inspired us with his dedication, invaluable knowledge and experience. He was a brilliant yet humble man, a superb scientist and a Johns Hopkins innovator,” said William Nelson, director of the Johns Hopkins Kimmel Cancer. “He will be sorely missed by countless residents, fellows and colleagues.”

He is survived by brother, Alan, and sister-in-law, Anne, as well as nieces and nephews.

Table of Contents

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login